Loading...
T-cell–engaging bispecific antibodies are approved as single-agent therapy for patients with relapsed myeloma who have received at least four prior lines of therapy including immunomodulatory agents, proteasome inhibitors, and an anti-CD38 monoclonal antibody. To assess the clinical utility of combining two bispecific agents with different myeloma cell antigenic targets, investigators conducted an industry-sponsored, multicenter, phase 1b–2 trial of talquetamab (anti-CD3 x anti-GPRC5D) plus teclistamab (anti-CD3 x anti-BCMA) in patients with relapsed or refractory myeloma.
Following the dose-escalation phase and utilizing a stepped-up dosing schedule to mitigate severe cytokine release syndrome (CRS), the investigators selected phase 2 doses…